Skip to content
Veracyte® Press Releases

Veracyte® Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces First Quarter 2022 Financial Results
Grew Total Revenue to $67.8 million , an Increase of 85% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 3, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2022 .
View HTML
Toggle Summary Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
Review article and commentary in AnnalsATS reinforce clinical utility of genomic test to improve confidence in IPF diagnosis, in conjunction with HRCT and clinical factors SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated
View HTML
Toggle Summary Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
Findings Provide New Insights into Genomic Underpinnings of Prostate and Bladder Cancers SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder
View HTML
Toggle Summary Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 26, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new, expanded data demonstrating the performance of the company’s non-invasive Percepta   Nasal Swab test in the evaluation of potentially cancerous lung nodules will be presented at
View HTML
Toggle Summary Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2022 after the close of market on Tuesday, May 3, 2022 . Company management will host a conference call and webcast to discuss
View HTML
Toggle Summary Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 1, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a presentation at Cowen’s 42 nd Annual Health Care Conference on March 8 th at
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results
Grew Fourth Quarter 2021 Revenue to $67.3 Million , an Increase of 95% Grew 2021 Revenue to $219.5 Million , an Increase of 87% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 28, 2022-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte Appoints Annie McGuire as General Counsel
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 28, 2022-- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately. Ms. McGuire will oversee all aspects of the company’s
View HTML
Toggle Summary Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 22, 2022-- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has appointed Jonathan Wygant as chief accounting officer, effective immediately. Mr. Wygant will oversee all aspects of the company’s global
View HTML
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 15, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2021 after the close of market on Monday, February 28, 2022 .
View HTML